FDA approves Roche ’s Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC).

https://www.roche.com/media/releases/med-cor-2019-08-16.htm

Source: Roche Media News - August 16, 2019 Category: Pharmaceuticals Source Type: news